Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans
NCT00243191
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
18
Enrollment
OTHER
Sponsor class
Conditions
Dermatofibrosarcoma Protuberans
Interventions
DRUG:
imatinib mesylate
Sponsor
Sarcoma Alliance for Research through Collaboration